These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 39037543)

  • 1. Liposomal irinotecan (HR070803) in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors: a phase 1b dose-escalation and expansion study.
    Ji D; Shen W; Li T; Wang H; Bai J; Cao J; Hu X
    Invest New Drugs; 2024 Aug; 42(4):462-470. PubMed ID: 39037543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I dose-escalation study of PEP02 (irinotecan liposome injection) in combination with 5-fluorouracil and leucovorin in advanced solid tumors.
    Chiang NJ; Chao TY; Hsieh RK; Wang CH; Wang YW; Yeh CG; Chen LT
    BMC Cancer; 2016 Nov; 16(1):907. PubMed ID: 27871319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanoliposomal irinotecan and fluorouracil plus leucovorin versus fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therapies (AIO NALIRICC): a multicentre, open-label, randomised, phase 2 trial.
    Vogel A; Saborowski A; Wenzel P; Wege H; Folprecht G; Kretzschmar A; Schütt P; Jacobasch L; Ziegenhagen N; Boeck S; Zhang D; Kanzler S; Belle S; Mohm J; Gökkurt E; Lerchenmüller C; Graeven U; Pink D; Götze T; Kirstein MM
    Lancet Gastroenterol Hepatol; 2024 Aug; 9(8):734-744. PubMed ID: 38870977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Irinotecan hydrochloride liposome HR070803 in combination with 5-fluorouracil and leucovorin in locally advanced or metastatic pancreatic ductal adenocarcinoma following prior gemcitabine-based therapy (PAN-HEROIC-1): a phase 3 trial.
    Cui J; Qin S; Zhou Y; Zhang S; Sun X; Zhang M; Cui J; Fang W; Gu K; Li Z; Wang J; Chen X; Yao J; Zhou J; Wang G; Bai Y; Xiao J; Qiu W; Wang B; Xia T; Wang C; Kong L; Yin J; Zhang T; Shen X; Fu D; Gao C; Wang H; Wang Q; Wang L
    Signal Transduct Target Ther; 2024 Sep; 9(1):248. PubMed ID: 39300077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I/II study.
    Wainberg ZA; Bekaii-Saab T; Boland PM; Dayyani F; Macarulla T; Mody K; Belanger B; Maxwell F; Moore Y; Thiagalingam A; Wang T; Zhang B; Dean A
    Eur J Cancer; 2021 Jul; 151():14-24. PubMed ID: 33957442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial.
    Alistar A; Morris BB; Desnoyer R; Klepin HD; Hosseinzadeh K; Clark C; Cameron A; Leyendecker J; D'Agostino R; Topaloglu U; Boteju LW; Boteju AR; Shorr R; Zachar Z; Bingham PM; Ahmed T; Crane S; Shah R; Migliano JJ; Pardee TS; Miller L; Hawkins G; Jin G; Zhang W; Pasche B
    Lancet Oncol; 2017 Jun; 18(6):770-778. PubMed ID: 28495639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Safety and efficacy of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) in Chinese patients with advanced colorectal cancer].
    Song Y; Li WW; Huang J
    Zhonghua Zhong Liu Za Zhi; 2017 May; 39(5):380-383. PubMed ID: 28535657
    [No Abstract]   [Full Text] [Related]  

  • 8. Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer.
    Mani S; Rudin CM; Kunkel K; Holmlund JT; Geary RS; Kindler HL; Dorr FA; Ratain MJ
    Clin Cancer Res; 2002 Apr; 8(4):1042-8. PubMed ID: 11948111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I dose-escalation study of intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours.
    Van Cutsem E; Khayat D; Verslype C; Billemont B; Tejpar S; Meric JB; Soussan-Lazard K; Assadourian S; Cartot-Cotton S; Rixe O
    Eur J Cancer; 2013 Jan; 49(1):17-24. PubMed ID: 22921183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer.
    Toffoli G; Cecchin E; Gasparini G; D'Andrea M; Azzarello G; Basso U; Mini E; Pessa S; De Mattia E; Lo Re G; Buonadonna A; Nobili S; De Paoli P; Innocenti F
    J Clin Oncol; 2010 Feb; 28(5):866-71. PubMed ID: 20038727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of oxaliplatin in combination with gemcitabine, irinotecan, and 5-fluorouracil/leucovorin (G-FLIE) in patients with metastatic solid tumors including adenocarcinoma of the pancreas.
    Olszewski AJ; Grossbard ML; Chung MS; Chalasani SB; Malamud S; Mirzoyev T; Kozuch PS
    J Gastrointest Cancer; 2013 Jun; 44(2):182-9. PubMed ID: 23208490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I/II study of irinotecan when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group Study.
    Glynne-Jones R; Falk S; Maughan TS; Meadows HM; Sebag-Montefiore D
    Br J Cancer; 2007 Feb; 96(4):551-8. PubMed ID: 17262086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of liposomal irinotecan (LY01610) in patients with advanced esophageal squamous cell carcinoma.
    Liu Y; Zhang B; Xu J; Wang X; Tang J; Huang J
    Cancer Chemother Pharmacol; 2021 Sep; 88(3):403-414. PubMed ID: 34031756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oxaliplatin plus irinotecan and leucovorin-modulated 5-fluorouracil triplet regimen every other week: a dose-finding study in patients with advanced gastrointestinal malignancies.
    Comella P; Casaretti R; De Rosa V; Avallone A; Izzo F; Fiore F; Lapenta L; Comella G
    Ann Oncol; 2002 Dec; 13(12):1874-81. PubMed ID: 12453855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, Fluorouracil, and leucovorin in patients with solid tumors.
    Goetz MP; Erlichman C; Windebank AJ; Reid JM; Sloan JA; Atherton P; Adjei AA; Rubin J; Pitot H; Galanis E; Ames MM; Goldberg RM
    J Clin Oncol; 2003 Oct; 21(20):3761-9. PubMed ID: 12963697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase 1b dose escalation study of erlotinib in combination with infusional 5-Fluorouracil, leucovorin, and oxaliplatin in patients with advanced solid tumors.
    Hanauske AR; Cassidy J; Sastre J; Bolling C; Jones RJ; Rakhit A; Fettner S; Brennscheidt U; Feyereislova A; Díaz-Rubio E
    Clin Cancer Res; 2007 Jan; 13(2 Pt 1):523-31. PubMed ID: 17255274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study.
    Park SJ; Kim H; Shin K; Hong TH; Suh JH; Lee MA
    BMC Cancer; 2021 Nov; 21(1):1176. PubMed ID: 34732161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I, pharmacokinetic, and pharmacodynamic study of two schedules of vorinostat in combination with 5-fluorouracil and leucovorin in patients with refractory solid tumors.
    Fakih MG; Fetterly G; Egorin MJ; Muindi JR; Espinoza-Delgado I; Zwiebel JA; Litwin A; Holleran JL; Wang K; Diasio RB
    Clin Cancer Res; 2010 Jul; 16(14):3786-94. PubMed ID: 20463088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I dose-finding study of biweekly irinotecan in combination with fixed doses of 5-fluorouracil/leucovorin, gemcitabine and cisplatin (G-FLIP) in patients with advanced pancreatic cancer or other solid tumors.
    Rachamalla R; Malamud S; Grossbard ML; Mathew S; Dietrich M; Kozuch P
    Anticancer Drugs; 2004 Mar; 15(3):211-7. PubMed ID: 15014353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer.
    Meyerhardt JA; Clark JW; Supko JG; Eder JP; Ogino S; Stewart CF; D'Amato F; Dancey J; Enzinger PC; Zhu AX; Ryan DP; Earle CC; Mayer RJ; Michelini A; Kinsella K; Fuchs CS
    Cancer Chemother Pharmacol; 2007 Oct; 60(5):661-70. PubMed ID: 17216531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.